Skip to main content
EJNMMI Physics

Table 2 Patient treatment other than PRRT (n = 20)

From: Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

Treatment

Number of patients, n (%)

Previous treatment

 

 Surgery

11 (55%)

 Liver-directed treatment

5 (25%)

  RFA

2 (10%)

  TACE

3 (15%)

 Somatostatin analogue

13 (65%)

 Cytotoxic chemotherapy

14 (70%)

 Everolimus

16 (80%)

Concomitant treatment

 

 Everolimus

3 (15%)

  1. RFA: radiofrequency ablation, TACE: transarterial chemoembolization
Back to article page